DNA repair
PARP inhibitors
breast cancer
homologous recombination
synthetic lethality
target therapy
Journal
Current cancer drug targets
ISSN: 1873-5576
Titre abrégé: Curr Cancer Drug Targets
Pays: Netherlands
ID NLM: 101094211
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
09
2022
revised:
20
01
2023
accepted:
06
02
2023
medline:
4
9
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
ppublish
Résumé
Breast and ovarian tumors with pathogenic variants in The objective of this study is to evaluate whether T47D breast cancer cell line was modified using small interfering RNA and CRISPR/Cas9 technology, to knockout the Treatment with niraparib and carboplatin exerted a synergistic effect on T47D- T47D
Sections du résumé
BACKGROUND
Breast and ovarian tumors with pathogenic variants in
OBJECTIVE
The objective of this study is to evaluate whether
METHODS
T47D breast cancer cell line was modified using small interfering RNA and CRISPR/Cas9 technology, to knockout the
RESULTS
Treatment with niraparib and carboplatin exerted a synergistic effect on T47D-
CONCLUSIONS
T47D
Identifiants
pubmed: 37076963
pii: CCDT-EPUB-131062
doi: 10.2174/1568009623666230418101511
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
900-909Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.